ISH(In Situ Hybridization) 시장 : 제품 유형, 감지 방법, 프로브 유형, 자동화 레벨, 처리 능력, 용도별 예측(2026-2032년)

The In Situ Hybridization Market is projected to grow by USD 2.94 billion at a CAGR of 7.65% by 2032.

In situ hybridization (ISH) is a core molecular pathology technique that localizes specific DNA or RNA sequences within intact cells and tissues, preserving spatial context that PCR and bulk sequencing can lose. The field spans fluorescence in situ hybridization (FISH), chromogenic ISH, silver ISH, RNA ISH, probes, assay kits, instruments, imaging systems, software, and services used across oncology, cytogenetics, infectious disease, neuroscience, developmental biology, and pharmaceutical research.

Demand is supported by measurable clinical need and expanding molecular diagnostics utilization. The WHO's cancer agency, IARC, reported nearly 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, reinforcing the need for precise tumor characterization, biomarker localization, and companion diagnostic workflows. ISH remains especially relevant for HER2 testing, gene rearrangement detection, viral localization, chromosomal abnormality assessment, and single-cell spatial analysis in translational research.

Transformative Shifts Reshaping In Situ Hybridization

The ISH landscape is shifting from manual, slide-by-slide workflows toward automated, multiplexed, and digital pathology-enabled platforms. Laboratories are prioritizing reproducibility, faster turnaround time, standardized staining, and integrated image analysis as pathology volumes rise and skilled workforce constraints persist across many health systems.

A second transformation is the convergence of ISH with spatial biology. RNA ISH and multiplex FISH allow researchers to map gene expression within tissue architecture, linking molecular signatures to the tumor microenvironment, immune infiltration, disease progression, and cellular heterogeneity. This is expanding ISH beyond confirmatory diagnostics into discovery research, biomarker validation, clinical trial support, and therapy-response studies.

Cumulative Impact of Artificial Intelligence on ISH

Artificial intelligence is accelerating ISH through automated cell detection, signal enumeration, tissue segmentation, image quality control, and assisted interpretation. In FISH assays, AI-assisted image analysis can reduce observer variability in signal counting, while digital pathology algorithms support more consistent review across distributed laboratory networks.

The impact is cumulative rather than isolated. AI improves pre-analytical review by flagging inadequate tissue, enhances analytical precision through pattern recognition, and strengthens post-analytical reporting by integrating ISH results with histology, immunohistochemistry, and genomic data. FDA's public AI/ML-enabled medical device list has expanded rapidly in recent years, showing regulatory momentum for clinical AI, although pathology applications still require rigorous validation, bias testing, cybersecurity controls, and laboratory-developed test governance.

Key Regional Insights Across Global ISH Adoption

North America demonstrates advanced ISH adoption through mature molecular pathology infrastructure, oncology testing reimbursement pathways, reference laboratory capacity, and strong translational research activity. The United States supports high-volume use in companion diagnostics, hematologic malignancy testing, cytogenetics, and solid tumor biomarker assessment, while Canada benefits from coordinated public health systems, cancer genomics programs, and accredited laboratory networks. Europe shows steady uptake, supported by cancer policy initiatives, external quality assessment participation, harmonized laboratory standards, and strong pathology communities across Germany, France, Italy, Spain, and the United Kingdom.

Asia-Pacific is a highly active region for ISH adoption as China, Japan, South Korea, India, and Australia expand precision medicine, cancer diagnostics, pharmaceutical R&D, and advanced imaging capabilities. Latin America is progressing through Brazil and Mexico, where increasing oncology burden, private diagnostic investment, and hospital modernization are strengthening demand for validated molecular assays. The Middle East, led by GCC health transformation programs, is investing in tertiary care, genomics, and specialized oncology centers, while Africa remains earlier-stage but clinically important because infectious disease research, cancer underdiagnosis, pathology workforce development, and expanding laboratory capacity create long-term demand for ISH workflows.

Key Group Insights for ISH Market Expansion

ASEAN markets are benefiting from hospital modernization, regional medical tourism, infectious disease surveillance, and expanding oncology testing, with Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines forming a diverse but increasingly connected diagnostics ecosystem. The GCC is prioritizing precision medicine through national health transformation programs, making molecular pathology, genomic medicine, and tertiary oncology capacity strategic priorities for leading hospitals.

The European Union provides regulatory structure, research funding, cross-border cancer initiatives, and quality assurance frameworks that support validated ISH workflows. BRICS countries represent scale and localization potential, with China, India, and Brazil adding large patient populations, expanding clinical trial ecosystems, and domestic life science manufacturing capacity. G7 markets remain technology leaders because of strong reimbursement systems, research funding, pathology accreditation, and pharmaceutical partnerships. NATO members overlap significantly with advanced diagnostic markets, where resilient supply chains, laboratory readiness, and access to critical reagents are increasingly viewed as strategic healthcare capabilities.

Key Country Insights Shaping ISH Demand

The United States remains a major innovation hub for ISH, supported by regulated diagnostics, high oncology testing intensity, clinical trial activity, and biopharma demand. Canada emphasizes standardized cancer care and accredited laboratory networks, while Mexico and Brazil are expanding molecular oncology access through private laboratories, public hospital investment, and growing demand for tumor biomarker testing. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain strong pathology networks, cancer research programs, and quality-controlled diagnostic pathways, while Russia retains scientific and clinical capacity but faces procurement, logistics, and technology access constraints.

China is scaling precision diagnostics, oncology infrastructure, and domestic life science manufacturing; India is expanding cancer testing from metropolitan centers into broader hospital networks as cancer incidence and diagnostic awareness rise; Japan and South Korea combine mature oncology care with strong imaging, automation, and laboratory quality systems; and Australia benefits from high-quality pathology accreditation, national cancer initiatives, and translational research programs. These countries collectively shape probe demand, automation adoption, assay validation priorities, digital pathology integration, and clinical evidence expectations across ISH applications.

Actionable Recommendations for ISH Industry Leaders

Industry leaders should prioritize automated, standardized, and multiplex-capable ISH solutions that reduce hands-on time, improve assay reproducibility, and limit inter-observer variability. Providers that pair high-quality probes with workflow integration, digital image management, validated AI-assisted interpretation, and strong technical support will be better positioned with hospital laboratories, academic medical centers, reference laboratories, and contract research organizations.

Commercial strategies should separate mature-market needs from emerging-market requirements. In G7 and EU countries, emphasis should be placed on companion diagnostics, spatial biology, interoperability, regulatory-grade evidence, and external quality assessment readiness. In Asia-Pacific, Latin America, the Middle East, and Africa, scalable pricing, training, service support, reagent availability, and partnerships with reference laboratories will be decisive. Leaders should also invest in supply-chain resilience for probes, reagents, controls, and instrumentation because assay continuity is critical in clinical diagnostics and regulated research.

Research Methodology

This executive summary is based on secondary research, regulatory review, and evidence triangulation using publicly available and verifiable sources, including WHO/IARC cancer statistics, FDA medical device and diagnostic guidance resources, OECD and national health system indicators, peer-reviewed pathology literature, clinical laboratory standards, public reimbursement information, and documented molecular pathology adoption trends.

The methodology evaluates demand drivers, technology adoption, regional healthcare capacity, reimbursement context, regulatory direction, quality assurance practices, and competitive positioning by application area. Insights were cross-validated across clinical diagnostics, research, and pharmaceutical use cases to avoid reliance on a single indicator. No unsupported market-size, market-share, or growth-rate claims are used; conclusions are grounded in observable disease burden, infrastructure investment, regulatory momentum, laboratory capability, and documented adoption of molecular pathology, spatial biology, and digital pathology workflows.

Conclusion

In situ hybridization remains essential because it combines molecular specificity with tissue-level spatial context. As oncology, infectious disease, cytogenetics, and translational research increasingly require localized biomarker evidence, ISH is positioned as both a mature diagnostic tool and a critical component of next-generation spatial biology.

The strongest opportunities will emerge where automation, AI-enabled interpretation, validated multiplexing, regulatory confidence, and regional access strategies converge. Organizations that can deliver reliable assays, digital workflow compatibility, quality-controlled interpretation, and practical laboratory support will help define the next phase of global ISH adoption.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. In Situ Hybridization Market, by Product Type

• 7.1. Instruments
  • 7.1.1. Automated Systems
  • 7.1.2. Manual Systems
• 7.2. Reagents
  • 7.2.1. Probes
  • 7.2.2. Product Kits
• 7.3. Services
  • 7.3.1. Consultation Services
  • 7.3.2. Custom Services
• 7.4. Software
  • 7.4.1. Data Analysis
  • 7.4.2. Image Analysis

8. In Situ Hybridization Market, by Detection Method

• 8.1. Chromogenic
• 8.2. Fluorescent
• 8.3. Radioactive

9. In Situ Hybridization Market, by Probe Type

• 9.1. DNA Probes
• 9.2. RNA Probes
• 9.3. Synthetic

10. In Situ Hybridization Market, by Automation Level

• 10.1. Manual
• 10.2. Semi-Automated
• 10.3. Fully Automated

11. In Situ Hybridization Market, by Throughput

• 11.1. Low
• 11.2. Medium
• 11.3. High

12. In Situ Hybridization Market, by Application

• 12.1. Cancer Diagnosis
• 12.2. Genetic Disorders
• 12.3. Infectious Diseases
• 12.4. Neuroscience
• 12.5. Developmental Biology
• 12.6. Drug Discovery & Research

13. In Situ Hybridization Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. In Situ Hybridization Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. In Situ Hybridization Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Abnova Corporation
• 17.3. Advanced Cell Diagnostics, Inc.
• 17.4. Agilent Technologies, Inc.
• 17.5. Akoya Biosciences, Inc.
• 17.6. Bio-Rad Laboratories, Inc.
• 17.7. Bio-Techne Corporation
• 17.8. Biocare Medical, LLC
• 17.9. BioGenex Laboratories, Inc.
• 17.10. Enzo Biochem, Inc.
• 17.11. Eurofins Scientific SE
• 17.12. F. Hoffmann-La Roche Ltd
• 17.13. Genemed Biotechnologies, Inc.
• 17.14. Leica Biosystems Nussloch GmbH
• 17.15. Merck KGaA
• 17.16. Molecular Instruments, Inc.
• 17.17. NanoString Technologies, Inc.
• 17.18. NeoGenomics Laboratories, Inc.
• 17.19. OriGene Technologies, Inc.
• 17.20. Oxford Gene Technology IP Limited
• 17.21. Qiagen N.V.
• 17.22. Thermo Fisher Scientific Inc.
• 17.23. Zytomed Systems GmbH